hATTR is a systemic autosomal dominant disorder characterized by the extracellular deposition of misfolded TTR protein. hATTR cases are divided into two segments which include Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases.
Hereditary transthyretin amyloidosis (hATTR), an inherited, rapidly progressive, and life-threatening disease, is caused by a mutation in the transthyretin (TTR) gene that results in misfolded TTR proteins accumulating as amyloid fibrils in multiple sites, including the nerves, heart, and gastrointestinal tract. TTR protein is produced primarily in the liver and is usually a carrier for retinol-binding protein—one of the media used to transport vitamin A around the body.
hATTR amyloidosis involves many systems in the body and can result in a wide variety of symptoms, including sensory and motor, autonomic (e.g., diarrhea, hypotension, erectile dysfunction), and cardiac symptoms.
DelveInsight's "Hereditary Transthyretin Amyloidosis (hATTR) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Hereditary Transthyretin Amyloidosis (hATTR) market Size and Share, historical and forecasted epidemiology analysis as well as the Hereditary Transthyretin Amyloidosis (hATTR) market trends in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Hereditary Transthyretin Amyloidosis (hATTR) Market Key Facts
-
In 2017, the total diagnosed prevalent population of hATTR in the 7MM was 11,330.
-
hATTR is segmented into two groups, i.e., Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2017, there were 5,241, and 6,089 diagnosed prevalent cases of FAP and FAC, respectively, in the 7MM.
-
The United States has the highest percentage of diagnosed prevalent population in 2017.
Hereditary Transthyretin Amyloidosis (hATTR) Market
The market size of Hereditary Transthyretin Amyloidosis (hATTR) shall increase during the forecast period (2020–2030), owing to the launch of upcoming therapies.
The Hereditary Transthyretin Amyloidosis (hATTR) market analysis report helps to build the detailed comprehension of the historic, current and forecasted Hereditary Transthyretin Amyloidosis (hATTR) market trends by evaluating the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology
The Hereditary Transthyretin Amyloidosis (hATTR) epidemiology analysis covers insights about historical and current Hereditary Transthyretin Amyloidosis (hATTR) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
Hereditary Transthyretin Amyloidosis (hATTR) Drugs Uptake and Key Market Players
The Hereditary Transthyretin Amyloidosis (hATTR) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Transthyretin Amyloidosis (hATTR) market or expected to get launched in the market during the study period. The analysis covers Hereditary Transthyretin Amyloidosis (hATTR) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Treatment options for hATTR amyloidosis are rapidly expanding. Recently few novel therapies are approved for the treatment of hATTR. Some of the key players in the Hereditary Transthyretin Amyloidosis (hATTR) market includes:
Ionis Pharmaceuticals
Akcea
Alnylam Pharmaceuticals
Prothena Corporation
Pfizer
And many others.
For more information on Hereditary Transthyretin Amyloidosis (hATTR) Market Size, Share, and Trends, visit: